期刊文献+

胰岛素样生长因子2引起Rh1肉瘤细胞mTOR信号的背景变化

Insulin-like growth factor-Ⅱ induces mTOR pathway change in Rh1 sarcoma cells
下载PDF
导出
摘要 目的观察胰岛素样生长因子(IGF)2对Rh1肉瘤细胞生长活性和mTOR信号背景的影响。方法常规培养Rh1细胞,均用无血清培养液消除内源性因子影响后再用IGF-2(终浓度为10 ng/ml)刺激,72 h后用流式细胞仪检测细胞生长活性;蛋白质印迹方法观察IGF-2刺激细胞5、10、20、30、60 min后S6、Akt(s473)的动态变化。结果与对照组相比,IGF-2刺激可促进Rh1细胞存活,降低细胞凋亡率;IGF-2刺激细胞后可使S6磷酸化随着时间的延长逐渐增强;IGF-2亦导致Akt(s473)位点的磷酸化,其磷酸化状态相对稳定。结论 IGF-2刺激Rh1细胞时,mTOR信号通路中S6功能逐渐增强,Akt功能则相对稳定。 Objective To observe the effect of insulinlike growth factor-Ⅱ(IGF-2) on the growth and the mTOR pathway of Rh1 sarcoma cells.Methods Rh1 cells were cultured routinely,and were treated with IGF-2 at a final concentration of 10 ng/ml after starving with pure RPMI 1640 medium.The growth of cells was analyzed by flow cytometry 72 h after IGF-2 treatment.The phosphorylation of S6 and Akt(s473) proteins were examined by Western blotting analysis at 5,10,20,30,and 60 min after IGF-2 treatment.Results IGF-2 treatment promoted the survival and inhibited the apoptosis of Rh1 cells compared with the control group.IGF-2 also increased the phosphorylation of S6 in a time-dependent manner.However,the phosphorylation of Akt(s473) was relatively stable in Rh1 cells.Conclusion IGF-2 can gradually increase the function of S6 in the mTOR pathway,and the function of Akt(s473) is kept relatively stable.
作者 黄文峰
出处 《第二军医大学学报》 CAS CSCD 北大核心 2011年第4期422-424,共3页 Academic Journal of Second Military Medical University
基金 湖北省卫生厅科研基金指导性项目(JX3C09)~~
关键词 胰岛素样生长因子Ⅱ Rh1肉瘤细胞 MTOR insulin like growth factor Ⅱ Rh1 sarcoma cells mTOR
  • 相关文献

参考文献8

  • 1罗荣城,姚广裕.肿瘤分子靶向治疗与生物化疗进展[J].中国肿瘤生物治疗杂志,2009,16(2):101-105. 被引量:23
  • 2Assouline S, Culjkovic B, Cocolakis E. Rousseau C, Beslu N, Amri A,et al. Molecular targeting of the oneogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical tri al with ribavirin[J]. Blood, 2009,114 : 257-260.
  • 3Gualberto A,Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology[J]. Curr Drug Targets, 2009,10 : 923-936.
  • 4Kurmasheva R T,Dudkin L,Billups C,Debelenko I. V,Morton C I., Houghton P J. The insulin like growth factor-1 receptortargeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma [J]. Cancer Res,2009,69:7662 7671.
  • 5陈洪菊(综述),李晋辉(综述),屈艺(审阅),母得志(审阅).mTOR信号通路与调节[J].医学分子生物学杂志,2009,6(6):542-546. 被引量:15
  • 6Sparks C A, Guertin D A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy [J]. Oncogene, 2010,29:3733-3744.
  • 7Opel D, Poremba C, Simon T, Debar in K M, Fulda S. Act ivation of Akt predicts poor outcome in neuroblastoma [J]. Cancer Res, 2007,67 : 735-745.
  • 8Dibble C C, Asara J M. Manning B D. Characterization of Rictor phosphorylation sites reveals direct regulation of roTOR com plex 2 by S6K1[J]. Mol Cell Biol,2009,29:5657-5670.

二级参考文献29

  • 1罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [ J ]. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 3Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors [ J ]. Cancer Control, 2007, 14 (3) : 295-304.
  • 4Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2-( triple negative (TNeg)) disease from N0234, a phase Ⅱ trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) [ EB/OL]. ( 2007 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/ cgi/ content/ abstract/ 25 /18_suppl/1071.
  • 5Munoz A, Salut A, Pericay C, et al. Phase Ⅱ trial of capecit- abine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib : XELOBER trial [ EB/OL ]. ( 2008 ) [ 2009-04-21 ]. http://meeting, ascopubs, org/cgi/content/abstract/26/15 _suppl./ 15078.9 maxtoshow = & HITS = 20 & hits = 20 & RESULTFOR- MAT = & fulhext =c. pericay & searchid = I&FIRSTINDEX =0 & resourcetype = HWCIT.
  • 6Von Minckwitz G, Zielinski C, Maartense E, et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment [ EB/OL]. (2008) [ 2009-04-21 ]. http://meeting, ascopubs. org/cgi/content/abstract/26/15 _suppl/1025.
  • 7Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer [ J]. Breast Cancer Rcs, 2005, 10 (4) : R60.
  • 8Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351 (4): 337- 345.
  • 9Milani M, Harris AL. Targeting tumour hypoxia in breast cancer [J]. Eur J Cancer, 2008, 44( 18): 2766-2773.
  • 10Rho JK, Choi YJ, Lee JK, et al. Gefitinib circumvents hypoxia- induced drug resistance by the modulation of HIF-lalpha[ J]. Oncol Rep, 2009, 21 (3) : 801-807.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部